- Home
- NUVL vs BWA Comparison
NUVL vs BWA Comparison
Compare NUVL & BWA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BWA
- Stock Information
- Founded
- NUVL 2017
- BWA 1987
- Country
- NUVL United States
- BWA United States
- Employees
- NUVL N/A
- BWA N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BWA Auto Parts:O.E.M.
- Sector
- NUVL Health Care
- BWA Consumer Discretionary
- Exchange
- NUVL Nasdaq
- BWA Nasdaq
- Market Cap
- NUVL 6.5B
- BWA 6.3B
- IPO Year
- NUVL 2021
- BWA 1993
- Fundamental
- Price
- NUVL $98.17
- BWA $44.14
- Analyst Decision
- NUVL Strong Buy
- BWA Buy
- Analyst Count
- NUVL 11
- BWA 14
- Target Price
- NUVL $121.45
- BWA $46.14
- AVG Volume (30 Days)
- NUVL 527.5K
- BWA 2.1M
- Earning Date
- NUVL 10-30-2025
- BWA 10-30-2025
- Dividend Yield
- NUVL N/A
- BWA 1.54%
- EPS Growth
- NUVL N/A
- BWA N/A
- EPS
- NUVL N/A
- BWA 0.61
- Revenue
- NUVL N/A
- BWA $14,183,000,000.00
- Revenue This Year
- NUVL N/A
- BWA $3.15
- Revenue Next Year
- NUVL N/A
- BWA $3.13
- P/E Ratio
- NUVL N/A
- BWA $72.34
- Revenue Growth
- NUVL N/A
- BWA 0.10
- 52 Week Low
- NUVL $55.54
- BWA $24.40
- 52 Week High
- NUVL $104.90
- BWA $44.97
- Technical
- Relative Strength Index (RSI)
- NUVL 60.96
- BWA 56.94
- Support Level
- NUVL $90.00
- BWA $43.11
- Resistance Level
- NUVL $99.94
- BWA $44.40
- Average True Range (ATR)
- NUVL 5.06
- BWA 1.06
- MACD
- NUVL 0.69
- BWA 0.08
- Stochastic Oscillator
- NUVL 66.81
- BWA 88.03
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BWA BorgWarner Inc.
BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2023, 25% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.